scholarly journals Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade

2016 ◽  
Vol 114 (7) ◽  
pp. 744-750 ◽  
Author(s):  
Hidenori Toyoda ◽  
Paul BS Lai ◽  
James O'Beirne ◽  
Charing C Chong ◽  
Sarah Berhane ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Curative Therapy ◽  
Long Term Impact

Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade

2018 ◽  
Vol 22 (7) ◽  
pp. 1230-1238 ◽  
Author(s):  
Hajime Matsushima ◽  
Yuko Takami ◽  
Tomoki Ryu ◽  
Munehiro Yoshitomi ◽  
Masaki Tateishi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Curative Therapy

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

2012 ◽  
pp. 261-264 ◽  
Author(s):  
Laura A. Dawson ◽  
Sameh Hashem ◽  
Alexis Bujold
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Liver Function ◽  
Randomized Trials ◽  
Stereotactic Body Radiation Therapy ◽  
Great Majority ◽  
High Dose ◽  
Dose Volume ◽  
Systemic Therapies

Overview: Stereotactic body radiotherapy (SBRT), in which highly conformal potent radiation doses are delivered in fewer fractions than traditional radiation therapy (RT), is an increasingly popular treatment for hepatocellular carcinoma (HCC). The great majority of HCCs smaller than 6 cm and with Child-Pugh A liver function are controlled with SBRT with limited toxicity. Long-term local control is reduced in larger tumors, and toxicity is increased in patients with Child-Pugh B or C liver function. SBRT is an effective treatment for tumor vascular thrombi and can lead to sustained vascular recanalization. The first site of recurrence following SBRT is most often within the liver, away from the high dose volume, providing rationale for combining SBRT with regional or systemic therapies. Randomized trials of SBRT are warranted.

Short- and long-term impact of reoperation for complications after major hepatectomy for hepatocellular carcinoma

Surgery ◽  
2016 ◽  
Vol 160 (5) ◽  
pp. 1236-1243 ◽  
Author(s):  
Wong Hoi She ◽  
Albert C.Y. Chan ◽  
Tan To Cheung ◽  
Kenneth S.H. Chok ◽  
Wing Chiu Dai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Major Hepatectomy ◽  
Short And Long Term ◽  
Long Term Impact

scholarly journals Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma

Nutrients ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1955 ◽  
Author(s):  
Atsushi Hosui ◽  
Eiji Kimura ◽  
Sumiko Abe ◽  
Takashi Tanimoto ◽  
Kousaku Onishi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Group ◽  
Liver Function ◽  
Cumulative Incidence ◽  
Zinc Supplementation ◽  
Incidence Rates ◽  
Zinc Enzymes ◽  
Zn Concentration ◽  
Serum Zn

Zinc plays a pivotal role in various zinc enzymes, which are crucial in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. Whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development remains unknown. Two hundred and sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients), were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were observed to be lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p < 0.001). According to serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dL (p < 0.001). Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dL.

Sign in / Sign up

Export Citation Format

Share Document